Against which mosquito-borne disease does this vaccine act?
Against which mosquito-borne disease does this vaccine act?
The Federal Commission for the Protection against Sanitary Risks (COFEPRIS) approved Dengvaxia for the prevention of disease caused by all four dengue virus serotypes in preadolescents, adolescents and adults, 9 to 45 years of age living in endemic areas.